23:12 , Jun 18, 2019 |  BC Innovations  |  Distillery Therapeutics

RLN2 injections to treat shoulder arthrofibrosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Injections of RLN2 could help treat shoulder arthrofibrosis, which manifests as long-standing restriction of joint range of motion. In a rat model of immobilization-induced shoulder arthrofibrosis, intra-articular injections of RLN2...
02:43 , Feb 28, 2019 |  BC Week In Review  |  Company News

Akcea gains as Novartis exercises option for CV risk reduction therapy

Akcea Therapeutics Inc. (NASDAQ:AKCA) added $4.57 (17%) to $31.91 on Feb. 25 after Novartis AG (NYSE:NVS; SIX:NOVN) exercised an option to license its antisense APOA1 inhibitor in a renewed attempt at CV risk reduction. Novartis...
21:51 , Feb 25, 2019 |  BC Extra  |  Company News

Akcea gains as Novartis exercises option for CV risk reduction therapy

Akcea Therapeutics Inc. (NASDAQ:AKCA) added $4.57 (17%) to $31.91 on Monday after Novartis AG (NYSE:NVS; SIX:NOVN) exercised an option to license its antisense APOA1 inhibitor in a renewed attempt at CV risk reduction. Novartis is...
23:43 , Nov 30, 2017 |  BC Week In Review  |  Company News

Moderna, AZ in relaxin mRNA therapeutic deal

Moderna Therapeutics Inc. (Cambridge, Mass.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to co-develop and co-commercialize AZD7970, which is in preclinical testing to treat heart failure. Moderna will be responsible for preclinical development, while AZ is...
04:12 , Sep 16, 2017 |  BioCentury  |  Strategy

Passing the baton

When he takes the helm as CEO of Novartis AG in January, Vasant Narasimhan will inherit a business that is still struggling to plug the revenue hole from cancer drug Gleevec imatinib going off patent...
21:21 , Jun 22, 2017 |  BC Extra  |  Clinical News

Novartis' canakinumab cuts CV risk in MI patients

Novartis AG (NYSE:NVS; SIX:NOVN) said canakinumab ( ACZ885 ) plus standard of care reduced cardiovascular risk in patients with a prior heart attack and inflammatory atherosclerosis in the Phase III CANTOS trial. The mAb against...
20:06 , Apr 28, 2017 |  BC Week In Review  |  Clinical News

Serelaxin: Development discontinued

Novartis said it discontinued development of serelaxin. In March, serelaxin missed the co-primary endpoints in the Phase III RELAX-AHF-2 trial to treat AHF (see BioCentury, March 24 ). In 2014, Endo gained exclusive, Canadian rights...
22:55 , Apr 25, 2017 |  BC Extra  |  Company News

Novartis confident in 2017 Entresto goal

Novartis AG (NYSE:NVS; SIX:NOVN) believes sales of heart failure drug Entresto sacubitril/valsartan can reach the company's $500 million goal this year, although the company's 1Q17 earnings report released Tuesday said sales were $84 million for...
20:16 , Mar 24, 2017 |  BC Week In Review  |  Clinical News

Serelaxin: Ph III RELAX-AHF-2 data

Novartis reported top-line data from the double-blind, international Phase III RELAX-AHF-2 trial in 6,600 patients hospitalized for AHF showing that an IV infusion of serelaxin for 48 hours plus standard of care (SOC) missed the...
21:00 , Mar 22, 2017 |  BC Extra  |  Clinical News

Novartis' serelaxin fails Phase III acute heart failure test

Novartis AG (NYSE:NVS; SIX:NOVN) said serelaxin (RLX030) missed the primary endpoints in the Phase III RELAX-AHF-2 trial in patients with acute heart failure (AHF). Compared to placebo, serelaxin plus standard of care (SOC) did not...